Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
about
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@en
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@nl
type
label
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@en
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@nl
prefLabel
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@en
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P1476
Phase 1 study of new formulati ...... ed non-small cell lung cancer.
@en
P2093
Emi Kamiyama
Hidetoshi Hayashi
Hironori Yamada
Kazuhiko Nakagawa
Kimio Yonesaka
Koji Haratani
Shoichi Ohwada
Toshio Shimizu
Tsutomu Iwasa
P2860
P2888
P304
P356
10.1007/S00280-016-3231-3
P577
2017-01-31T00:00:00Z